SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) Moat Score: 0/10 (As of Jul. 05, 2026)


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
70 GF Score
Price $0.47
GF Value $0.55
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Moat Score?

Shenzhen Hepalink Pharmaceutical Group Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Shenzhen Hepalink Pharmaceutical Group Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Shenzhen Hepalink Pharmaceutical Group Co might have No Moat - No discernible moat.

Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Shenzhen Hepalink Pharmaceutical Group Co Moat Score Related Terms

SHEZF
70GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 14.6% below its estimated GF Value™ of $0.55.

Key valuation signals for SHEZF:

  • Moat Score: 0
  • GF Value™: $0.55 vs. price of $0.47 (14.6% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
70GF Score

Get the complete analysis for SHEZF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.55
GF Value